BlackRock, Inc. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-26 11:49 am Purchase | 2023-12-31 | 13G | AKERO THERAPEUTICS INC AKRO | BlackRock, Inc. BLK | 4,180,507 7.500% | 1,421,978 (+51.55%) | Filing |
| 2023-02-03 12:09 pm Purchase | 2022-12-31 | 13G | AKERO THERAPEUTICS INC AKRO | BlackRock, Inc. BLK | 2,758,529 5.900% | 494,286 (+21.83%) | Filing |
| 2022-11-09 2:21 pm Unchanged | 2021-10-31 | 13G | AKERO THERAPEUTICS INC AKRO | BlackRock, Inc. BLK | 2,264,243 4.900% | 0 (Unchanged) | Filing |
| 2022-11-09 1:53 pm Sale | 2021-10-31 | 13G | AKERO THERAPEUTICS INC AKRO | BlackRock, Inc. BLK | 2,264,243 4.900% | -284,065,597 (-99.21%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | AKERO THERAPEUTICS INC AKRO | BlackRock, Inc. BLK | 1,944,122 5.600% | 1,944,122 (New Position) | Filing |